rhPSMA-7.3 (18F)

Phase 3Radiopharmaceutical

BBlue Earth Diagnostics

rhPSMA-7.3 (18F) is one of 29 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerCompleted

Prostate CancerPhase 3

Completed

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

48 2

Acetylsalicylic Acid

Bayer

Phase 3

2 3

Piflufolastat F 18

Novartis

Phase 3

1 4

rhPSMA-7.3 (18F)

BBlue Earth Diagnostics

Phase 3

4 5

Antibiotic Prophylaxis

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 6

Trexall

Jazz Pharmaceuticals

Preclinical

—7

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 8

Duragesic

CCephalon

Preclinical

1 9

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 10

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer4 trials

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

Recruiting·MMidLantic Urology·Phase 3·NCT05799248·113 enrolled

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

Completed·BBlue Earth Diagnostics·Phase 3·NCT04186845·391 enrolled

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

Completed·BBlue Earth Diagnostics·Phase 3·NCT04186819·356 enrolled

Show 1 more trial

Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

Completed·BBlue Earth Diagnostics·Phase 1·NCT03995888·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for rhPSMA-7.3 (18F). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rhPSMA-7.3 (18F) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rhPSMA-7.3 (18F). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Blue Earth Diagnostics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 3[1]
Company: BBlue Earth Diagnostics

rhPSMA-7.3 (18F)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer4 trials

References

Drug Info

Quick Facts

Related News